Inspire Medical Systems, Inc. Selling, General and Administrative Expense
Inspire Medical Systems, Inc. (INSP) reported Selling, General and Administrative Expense of $147.28 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-03
- Inspire Medical Systems, Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $147.28M, a 7.68% decline year-over-year.
- Inspire Medical Systems, Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $152.20M, a 5.48% increase year-over-year.
- Inspire Medical Systems, Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $161.95M, a 14.45% increase year-over-year.
- Inspire Medical Systems, Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $158.87M, a 21.84% increase year-over-year.
- Inspire Medical Systems, Inc. selling, general and administrative expense for fiscal 2025 was $624.64M, a 17.94% increase from fiscal 2024.
- Inspire Medical Systems, Inc. selling, general and administrative expense for fiscal 2024 was $529.61M, a 17.18% increase from fiscal 2023.
- Inspire Medical Systems, Inc. selling, general and administrative expense for fiscal 2023 was $451.96M, a 40.93% increase from fiscal 2022.
- Inspire Medical Systems, Inc. selling, general and administrative expense for fiscal 2022 was $320.69M, a 58.27% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $147.28M 10-Q · filed 2026-08-03 | $299.48M 10-Q · filed 2026-08-03 | $461.43M derived: sum of 3 quarters · filed 2026-08-03 | $620.30M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $152.20M 10-Q · filed 2026-05-04 | $314.16M derived: sum of 2 quarters · filed 2026-05-04 | $473.03M derived: sum of 3 quarters · filed 2026-05-04 | $632.55M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $161.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $320.83M derived: sum of 2 quarters · filed 2026-02-13 | $480.35M derived: sum of 3 quarters · filed 2026-08-03 | $624.64M 10-K · filed 2026-02-13 |
| 2025-09-30 | $158.87M 10-Q · filed 2025-11-03 | $318.39M derived: sum of 2 quarters · filed 2026-08-03 | $462.68M 10-Q · filed 2025-11-03 | $604.19M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $159.52M 10-Q · filed 2026-08-03 | $303.81M 10-Q · filed 2026-08-03 | $445.32M derived: sum of 3 quarters · filed 2026-08-03 | $575.71M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $144.29M 10-Q · filed 2026-05-04 | $285.80M derived: sum of 2 quarters · filed 2026-05-04 | $416.19M derived: sum of 3 quarters · filed 2026-05-04 | $548.28M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $141.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $271.90M derived: sum of 2 quarters · filed 2026-02-13 | $403.99M derived: sum of 3 quarters · filed 2026-02-13 | $529.61M 10-K · filed 2026-02-13 |
| 2024-09-30 | $130.39M 10-Q · filed 2025-11-03 | $262.48M derived: sum of 2 quarters · filed 2025-11-03 | $388.10M 10-Q · filed 2025-11-03 | |
| 2024-06-30 | $132.08M 10-Q · filed 2025-08-04 | $257.70M 10-Q · filed 2025-08-04 | ||
| 2024-03-31 | $125.62M 10-Q · filed 2025-05-05 | |||
| 2023-12-31 | $451.96M 10-K · filed 2026-02-13 | |||
| 2022-12-31 | $320.69M 10-K · filed 2025-02-10 | |||
| 2021-12-31 | $202.62M 10-K · filed 2024-02-09 | |||
| 2020-12-31 | $127.87M 10-K · filed 2023-02-10 | |||
| 2019-12-31 | $90.47M 10-K · filed 2022-02-15 | |||
| 2018-12-31 | $53.53M 10-K · filed 2021-02-24 | |||
| 2017-12-31 | $32.36M 10-K · filed 2020-02-25 | |||
| 2016-12-31 | $22.68M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NovoCure Ltd (NVCR) | $1.886B | -11.87 | |
| LEMAITRE VASCULAR INC (LMAT) | United States | $1.848B | 33.37 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |